Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine

Giménez-Sánchez, Francisco; Kieninger, Dorothee; Kueper, Kathrin; Martinón-Torres, Federico; Bernaola, Enrique; Díez-Domingo, Javier; Steul, Kathrin; Juergens, Christine; Gurtman, Alejandra; Giardina, Peter C.; Liang, John Z.; Gruber, William C.; Emini, Emilio A.; Scott, Daniel A.

doi:10.1016/j.vaccine.2011.06.026

Cited by 20 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In comparison with available literature on humoral responses to Infanrix hexa ® at the age of 15 months [29,30], the pertussis specific antibody titers were lower in our study, at both time points in both study groups. Gimenez-Sanchez et al [29] collected blood samples after a fourth dose of Infanrix hexa ® at 11-15 months of age, concomitantly administered with PCV 7 or PCV 13. Tichmann et al [30] collected blood samples both before and after a fourth dose of Infanrix hexa ® at 12-19 months of age.…”

Section: Discussionsupporting

confidence: 48%

Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age

Maertens

Caboré

Huygen

et al. 2016

Vaccine

View full text Add to dashboard Cite

Vaccination of pregnant women with a pertussis containing vaccine is a recommended strategy in some industrialized countries, to protect young infants from severe disease. One of the effects of the presence of high titers of passively acquired maternal antibodies in young infants is blunting of immune responses to infant vaccination. We present infant immune responses to a fourth pertussis containing vaccine dose at 15 months of age, as a follow-up of previously presented data. In a prospective cohort study, women were either vaccinated with an acellular pertussis vaccine (Boostrix(®)) during pregnancy (vaccine group) or received no vaccine (control group). All infants were vaccinated with Infanrix Hexa(®) according to the standard Belgian vaccination schedule (8/12/16 weeks, 15 months). We report results from blood samples collected before and 1 month after the fourth vaccine dose. Immunoglobulin G (IgG) antibodies against pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), tetanus toxoid (TT) and diphtheria toxoid (DT) were measured using commercially available ELISA tests. Antibody levels were expressed in International Units per milliliter. Demographic characteristics were similar in the vaccine and control group. Before the fourth vaccine dose, significantly lower antibody titers were measured in the vaccine group compared to the control group for anti-Prn IgG (p=0.003) and anti-DT IgG (p=0.023), with a steep decay of antibody titers since post-primary vaccination. One month after the fourth dose, antibody titers were only significantly lower in the vaccine group for anti-PT IgG (p=0.006). For all antigens, there was a rise in antibody titer after the fourth vaccine dose. The present results indicate still a minor blunting effect 1 month after a fourth vaccine dose for anti-PT antibodies. However, a good humoral immune response on all measured antigens was elicited in both groups of children. The clinical significance of such blunting effect is yet unknown. Clinicaltrials.gov identifier: NCT01698346.

show abstract

Section: Discussionsupporting

confidence: 48%

Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age

Maertens

Caboré

Huygen

et al. 2016

Vaccine

View full text Add to dashboard Cite

show abstract

“…In comparison with the available literature on general infant humoral immune responses to a booster dose of Infanrix Hexa in the second year of life [18, 19], some slight differences were found. Tichmann et al [18] collected blood samples after a fourth dose of Infanrix Hexa administered at 12–19 months of age.…”

Section: Discussionmentioning

confidence: 90%

“…Tichmann et al [18] collected blood samples after a fourth dose of Infanrix Hexa administered at 12–19 months of age. And Gimenez-Sanchez et al [19] collected blood samples after a fourth dose of Infanrix Hexa at 11–15 months of age, administered concomitantly with 7- or 13-valent pneumococcal conjugate vaccine. Different laboratory tests were used in both studies compared to this study.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Maternal Pertussis Immunization on Infant Vaccine Responses to a Booster Pertussis-Containing Vaccine in Vietnam

et al. 2016

View full text Add to dashboard Cite

Background. Maternal vaccination with an acellular pertussis (aP)–containing vaccine is a recommended strategy in a growing number of industrialized countries, to protect young infants from disease. Little is known on the effect of this strategy in low- and middle-income countries. Following a previous report on the effect of adding a pertussis and diphtheria component to the tetanus vaccination program in pregnant women in Vietnam, we report on infant immune responses to a booster aP vaccine dose in this randomized controlled clinical trial.Methods. Thirty infants of Tdap (tetanus, diphtheria, and acellular pertussis)–vaccinated pregnant women and 37 infants of women vaccinated with a tetanus-only vaccine received a fourth aP-containing vaccine dose in the second year of life. Blood was taken 1 month after the fourth infant dose. Immunoglobulin G (IgG) antibodies against pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), tetanus toxoid (TT), and diphtheria toxoid (DT) were measured using commercially available enzyme-linked immunosorbent assays (ELISA).Results. One month after the booster dose, significantly lower antibody titers were measured in the Tdap group for anti-TT IgG (P < .001) only. Anti-DT IgG, anti-PT IgG, anti-Prn IgG, and anti-FHA IgG antibody titers were comparable for both groups. A rise in antibody concentrations was elicited for all (except DT) antigens after boosting.Conclusions. The present results indicate that the blunting of infant pertussis responses induced by maternal immunization, measured after a primary series of aP vaccines, was resolved with the booster aP vaccine dose. These results add to the evidence for national and international decision makers on maternal immunization as a vaccination strategy for protection of young infants against infectious diseases.

show abstract

“…After duplicates (87) were ruled out and the title and abstract (171) were screened, we retrieved 15 potentially relevant studies for inclusion criteria and data extraction. Six studies were excluded [17][18][19][20][21][22] because of various reasons (data not shown, adult study, no comparison), and finally, a total of nine randomized clinical trials fulfilled all inclusion criteria and were selected in order to perform the systematic review and meta-analysis. Fig.…”

Section: Study Identification and Selectionmentioning

confidence: 99%

Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: A meta-analysis

Ruiz-Aragón

Peláez

Molina-Linde

et al. 2013

Vaccine

View full text Add to dashboard Cite

Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine

Cited by 20 publications

References 23 publications

Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age

Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age

The Effect of Maternal Pertussis Immunization on Infant Vaccine Responses to a Booster Pertussis-Containing Vaccine in Vietnam

Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: A meta-analysis

Contact Info

Product

Resources

About